199 related articles for article (PubMed ID: 36170375)
81. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
[TBL] [Abstract][Full Text] [Related]
82. Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S
Blood Cancer J; 2020 Dec; 10(12):125. PubMed ID: 33318477
[TBL] [Abstract][Full Text] [Related]
83. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Leung-Hagesteijn C; Erdmann N; Cheung G; Keats JJ; Stewart AK; Reece DE; Chung KC; Tiedemann RE
Cancer Cell; 2013 Sep; 24(3):289-304. PubMed ID: 24029229
[TBL] [Abstract][Full Text] [Related]
84. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
85. Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma.
Guo J; Lv Y; Wang S; Peng Z; Xie Y; Wang Y; Jiang H; Li X; Wang M; Hu M; Mu J; Wang J; Xie Y; Cheng X; Zhao Z; Liu Z
Oncogene; 2022 Nov; 41(45):4971-4979. PubMed ID: 36209257
[TBL] [Abstract][Full Text] [Related]
86. Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
Hu H; Petrosyan A; Osna NA; Liu T; Olou AA; Alakhova DY; Singh PK; Kabanov AV; Faber EA; Bronich TK
J Control Release; 2019 Jul; 306():149-164. PubMed ID: 31121280
[TBL] [Abstract][Full Text] [Related]
87. An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.
Przedborski M; Sharon D; Cathelin S; Chan S; Kohandel M
PLoS Comput Biol; 2022 Sep; 18(9):e1010439. PubMed ID: 36099249
[TBL] [Abstract][Full Text] [Related]
88. Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression.
Ning N; Zhang S; Wu Q; Li X; Kuang D; Duan Y; Xia M; Liu H; Weng J; Ba H; Tang Z; Cheng X; Mei H; Huang L; Ao Q; Wang G; Hu Y; Laurence A; Wang J; Wang G; Yang XP
Theranostics; 2022; 12(12):5537-5550. PubMed ID: 35910796
[No Abstract] [Full Text] [Related]
89. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
90. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B
Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360
[TBL] [Abstract][Full Text] [Related]
91. [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Iida S; Ri M
Rinsho Ketsueki; 2014 Mar; 55(3):304-10. PubMed ID: 24681933
[No Abstract] [Full Text] [Related]
92. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.
Touzeau C; Dousset C; Le Gouill S; Sampath D; Leverson JD; Souers AJ; Maïga S; Béné MC; Moreau P; Pellat-Deceunynck C; Amiot M
Leukemia; 2014 Jan; 28(1):210-2. PubMed ID: 23860449
[No Abstract] [Full Text] [Related]
93. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A; Bernal-Mizrachi L; Vertino P; Sun SY; Chen J; Munshi N; Fu H; Kowalski J; Boise LH; Lonial S
Leukemia; 2018 Mar; 32(3):744-751. PubMed ID: 28924240
[TBL] [Abstract][Full Text] [Related]
94. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956
[TBL] [Abstract][Full Text] [Related]
95. Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.
Adam K; Lambert M; Lestang E; Champenois G; Dusanter-Fourt I; Tamburini J; Bouscary D; Lacombe C; Zermati Y; Mayeux P
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26500282
[TBL] [Abstract][Full Text] [Related]
96. Venetoclax in myeloma: to B, or not to B.
Raab MS
Blood; 2024 Jan; 143(1):4-5. PubMed ID: 38175678
[No Abstract] [Full Text] [Related]
97. Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy.
Nair R; Gupta P; Shanmugam M
Front Oncol; 2022; 12():1000106. PubMed ID: 36185202
[TBL] [Abstract][Full Text] [Related]
98. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma.
Findlay S; Nair R; Merrill RA; Kaiser Z; Cajelot A; Aryanpour Z; Heath J; St-Louis C; Papadopoli D; Topisirovic I; St-Pierre J; Sebag M; Kesarwala AH; Hulea L; Taylor EB; Shanmugam M; Orthwein A
Blood Adv; 2023 Jul; 7(14):3485-3500. PubMed ID: 36920785
[TBL] [Abstract][Full Text] [Related]
99. Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production.
Ramos-Acosta C; Huerta-Pantoja L; Salazar-Hidalgo ME; Mayol E; Jiménez-Vega S; García-Peña P; Jordi-Cruz J; Baquero C; Porras A; Íñigo-Rodríguez B; Benavente CM; López-Pastor AR; Gómez-Delgado I; Urcelay E; Candel FJ; Anguita E
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732105
[TBL] [Abstract][Full Text] [Related]
100. Phototherapy techniques for the management of musculoskeletal disorders: strategies and recent advances.
Zhang Z; Wang R; Xue H; Knoedler S; Geng Y; Liao Y; Alfertshofer M; Panayi AC; Ming J; Mi B; Liu G
Biomater Res; 2023 Nov; 27(1):123. PubMed ID: 38017585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
